WO2026021380 - PCSK9 AND HMG-COA DUAL-TARGET COMPOUND AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/021380
Publication Date
29.01.2026
International Application No.
PCT/CN2025/109569
International Filing Date
21.07.2025
Title **
[English]
PCSK9 AND HMG-COA DUAL-TARGET COMPOUND AND USE THEREOF
[French]
COMPOSÉ À DOUBLE CIBLE PCSK9 ET HMG-COA ET SON UTILISATION
[Chinese]
PCSK9和HMG-CoA双靶化合物与应用
Applicants **
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD
Inventors
LAI, Yingjie
LI, Zhongle
XIAO, Ying
LI, Hongchao
QING, Zhineng
QI, Yinliang
WU, Kang
ZENG, Junnan
Priority Data
202410986157.X
22.07.2024
CN
202411428721.2
12.10.2024
CN
202411577204.1
05.11.2024
CN
202411805158.6
09.12.2024
CN
202510216980.7
26.02.2025
CN
202510480179.3
16.04.2025
CN
202510656911.8
20.05.2025
CN
202510945820.6
09.07.2025
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2235 | |
| EPO | Filing, Examination, Granting | 12146 | |
| Japan | Filing, Examination, Granting | 2124 | |
| South Korea | Filing, Examination, Granting | 2300 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
24,145
Contact Us
Abstract[English]
The present invention belongs to the technical field of chemical drugs, and relates to a PCSK9 and HMG-CoA dual-target compound, or an isomer thereof, or a racemate thereof, or a pharmaceutically acceptable salt thereof, a preparation method therefor, the use thereof as a PCSK9 inhibitor and/or HMG-CoA reductase inhibitor, and a method for using same to treat a plurality of specific diseases or disorders.[French]
La présente invention appartient au domaine technique des médicaments chimiques, et concerne un composé à double cible PCSK9 et HMG-CoA, ou un isomère de celui-ci, ou un racémate de celui-ci, ou un sel pharmaceutiquement acceptable de celui-ci, son procédé de préparation, son utilisation en tant qu'inhibiteur de PCSK9 et/ou inhibiteur de HMG-CoA réductase, et son procédé d'utilisation pour traiter une pluralité de maladies ou de troubles spécifiques.[Chinese]
本发明属于化学药物技术领域，涉及PCSK9和HMG-CoA双靶化合物，或其异构体、或其消旋体、或其可药用的盐，及其制备方法与应用。作为一种PCSK9抑制剂和/或HMG-CoA还原酶抑制剂，以及使用其治疗多种特定疾病或病状的方法。